Lung Cancer Panel 4: Comprehensive Genetic Testing for Personalized Treatment
Understanding the Lung Cancer Panel 4 Test
The Lung Cancer Panel 4 represents a cutting-edge advancement in precision oncology, specifically designed to analyze key genetic biomarkers that drive lung cancer progression and treatment response. This comprehensive molecular profiling test examines five critical biomarkers: EGFR, ALK1, ROS1, MET, and PD-L1, providing oncologists with essential information to develop personalized treatment strategies for patients with non-small cell lung cancer (NSCLC).
In today’s era of precision medicine, understanding the genetic makeup of lung cancer has become fundamental to achieving optimal treatment outcomes. This panel bridges the gap between traditional cancer diagnosis and modern targeted therapy approaches, enabling healthcare providers to match patients with the most effective treatments based on their tumor’s specific genetic characteristics.
What the Test Measures and Detects
Comprehensive Biomarker Analysis
The Lung Cancer Panel 4 utilizes sophisticated laboratory techniques including FISH (Fluorescence In Situ Hybridization) and Sanger Sequencing to detect:
- EGFR Mutations: Epidermal Growth Factor Receptor mutations that predict response to EGFR tyrosine kinase inhibitors
- ALK1 Rearrangements: Anaplastic Lymphoma Kinase gene fusions that indicate sensitivity to ALK inhibitors
- ROS1 Rearrangements: ROS proto-oncogene 1 fusions that respond to specific targeted therapies
- MET Amplifications: Mesenchymal-epithelial transition factor gene amplifications that may influence treatment selection
- PD-L1 Expression: Programmed Death-Ligand 1 protein levels that predict immunotherapy response
Who Should Consider This Test
Clinical Indications and Symptoms
This comprehensive genetic panel is particularly valuable for patients who:
- Have been newly diagnosed with non-small cell lung cancer
- Are experiencing treatment resistance with current therapies
- Present with advanced or metastatic lung cancer
- Have a history of smoking or environmental exposure risks
- Show symptoms including persistent cough, chest pain, shortness of breath, or unexplained weight loss
- Have family history of lung cancer or genetic predisposition
- Require treatment optimization after initial diagnosis
Benefits of Taking the Lung Cancer Panel 4 Test
Advantages of Comprehensive Genetic Profiling
Undergoing this advanced genetic testing provides numerous clinical benefits:
- Personalized Treatment Planning: Enables selection of targeted therapies based on specific genetic alterations
- Improved Treatment Outcomes: Increases likelihood of positive response to chosen therapies
- Avoidance of Ineffective Treatments: Prevents unnecessary exposure to treatments unlikely to work
- Comprehensive Molecular Profile: Provides multiple biomarker results from a single test
- Clinical Trial Eligibility: Identifies patients who may qualify for specific clinical trials
- Prognostic Information: Offers insights into disease progression and potential outcomes
- Cost-Effective Approach: Single comprehensive test reduces need for multiple individual tests
Understanding Your Test Results
Interpreting Genetic Findings
Your test results will provide detailed information about each biomarker analyzed:
- Positive EGFR Mutation: Indicates potential response to EGFR-targeted therapies like gefitinib, erlotinib, or osimertinib
- ALK1 Rearrangement Detected: Suggests benefit from ALK inhibitors such as crizotinib or alectinib
- ROS1 Fusion Positive: Points to potential effectiveness of ROS1-targeted treatments
- MET Amplification Present: May influence treatment decisions and clinical trial eligibility
- PD-L1 Expression Levels: High expression typically indicates better response to immunotherapy
It’s crucial to discuss your results with your oncologist, who will interpret the findings in the context of your specific clinical situation and develop a personalized treatment plan.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | Lung Cancer Panel 4: EGFR, ALK1, ROS1, MET, PD-L1 |
| Discount Price | $750 USD |
| Regular Price | $1,000 USD |
| Turnaround Time | 5-7 days |
| Sample Type | Tumor tissue (paraffin embedded tissue blocks) |
| Testing Methods | FISH, Sanger Sequencing |
| Prescription Required | Doctor’s prescription required (exceptions for surgery, pregnancy, and international travel) |
Nationwide Testing Availability
We have testing facilities conveniently located across the United States, serving major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified laboratories ensures consistent, high-quality testing standards nationwide.
Take the Next Step Toward Personalized Cancer Care
Don’t leave your lung cancer treatment to chance. The Lung Cancer Panel 4 provides the critical genetic information needed to make informed treatment decisions and potentially improve your treatment outcomes. Our team of genetic specialists and oncology experts are ready to assist you throughout the testing process.
Ready to get started? Book your Lung Cancer Panel 4 test today by calling our dedicated healthcare line at +1(267) 388-9828 or schedule your appointment online. Take control of your cancer journey with comprehensive genetic insights that can guide your treatment path.
